Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

60.68 +0.54 (+0.90%)

Streaming Delayed Price Updated: 3:56 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗

Today 12:20 EST

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 01, 2026

Could these three stocks be Cathie Wood's next big winners?

Via The Motley Fool

Topics ETFs

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗

February 20, 2026

The past few years have been challenging for the biotech.

Via The Motley Fool

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗

February 20, 2026

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Via The Motley Fool

Topics ETFs

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗

February 19, 2026

Via MarketBeat

Should You Buy Shares of CRISPR Therapeutics in February? ↗

February 18, 2026

The company could finally be ready to deliver on years of promise.

Via The Motley Fool

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗

February 13, 2026

2026 could be a big year for this company.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗

February 13, 2026

A sales partner offered a ray of hope that this company couldn't for itself.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 30, 2026

Opportunity knocks thrice for the iconic growth investor.

Via The Motley Fool

Topics Artificial Intelligence

Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗

January 29, 2026

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Via The Motley Fool

Topics Artificial Intelligence

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗

January 27, 2026

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core...

Via Benzinga

2 Biotech Stocks That Could Soar This Year ↗

January 12, 2026

And, if all goes well, over the next five years as well.

Via The Motley Fool

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗

December 26, 2025

There are some risks to consider before jumping on the bandwagon.

Via The Motley Fool

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

Via The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

December 23, 2025

All three companies' businesses are on the verge of long-term growth explosions.

Via The Motley Fool

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Next year could be crucial for the company as sales for its only approved treatment could take off.

Via The Motley Fool

2 Growth Stocks to Invest $1,000 in Right Now ↗

December 18, 2025

These stocks have promising assets in their portfolios that could help make their valuations soar in the future.

Via The Motley Fool

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

December 16, 2025

Issued on behalf of Avant Technologies Inc.

From USA News Group

Via GlobeNewswire

2 Monster Stocks in the Making to Buy and Hold ↗

December 16, 2025

The next 12 months will tell us more about their prospects.

Via The Motley Fool

12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗

December 15, 2025

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Via The Motley Fool

Topics Artificial Intelligence

2 Healthcare Stocks to Buy Ahead of the New Year ↗

December 12, 2025

These companies could innovate their way to success.

Via The Motley Fool

2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗

December 07, 2025

This juicy upside potential comes at a cost.

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗

November 30, 2025

This company's first product has started to generate revenue.

Via The Motley Fool

Topics ETFs

The Best Stocks to Buy With $1,000 Right Now ↗

November 29, 2025

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Via The Motley Fool

Topics Artificial Intelligence Energy

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗

November 21, 2025

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Via The Motley Fool

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.